Vyleesi Titration in Renal Impairment: What Women Need to Know

What Is Vyleesi and Why Does Kidney Function Matter?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist that acts primarily on MC1R and MC4R receptors in the brain to increase sexual desire. The FDA approved it in June 2019 under the brand name Vyleesi specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. You inject it with a single-use auto-injector into the abdomen or thigh at least 45 minutes before anticipated sexual activity.

The kidneys are a primary route of bremelanotide elimination. Approximately 64.8% of a bremelanotide dose is excreted in urine, with the rest cleared via feces. When kidney function falls, drug clearance slows, plasma concentrations rise, and side effects that are already dose-related, particularly nausea and blood pressure changes, can become more pronounced. That is the core reason renal function is not just a background detail here. It directly shapes how your body handles every dose.

How Bremelanotide Is Processed in the Body

After subcutaneous injection, bremelanotide reaches peak plasma concentration (Tmax) in about 1 hour. Its half-life is roughly 2.7 hours in women with normal renal function. Metabolism is primarily hydrolysis of the amide bonds, producing peptide fragments that the kidneys then clear. No single cytochrome P450 enzyme drives the main metabolic pathway, which simplifies drug-drug interaction concerns, but it also means the kidneys carry more of the excretion burden than they would for a heavily CYP-metabolized molecule.

Why Women's Kidney Function Differs from Men's

Women tend to have lower baseline glomerular filtration rates than men of the same age, partly because of smaller kidney mass relative to body surface area. This difference is factored into the eGFR equations (CKD-EPI, MDRD) used to classify chronic kidney disease (CKD) stages. Because Vyleesi is approved only for premenopausal women, the renal impairment pharmacokinetic (PK) sub-studies in the label are particularly relevant to your sex. Women were included in the dedicated renal impairment PK studies, and the label recommendations are based on those data.

The FDA Label Guidance on Renal Impairment Titration

The prescribing information for bremelanotide includes a specific dedicated section on use in renal impairment, based on a clinical pharmacology study comparing drug exposure across renal function groups.

Mild Renal Impairment (eGFR 60-89 mL/min)

No dose adjustment is needed. The area under the curve (AUC) for bremelanotide increased by approximately 37% in women with mild renal impairment compared with normal renal function, but this increase was not considered clinically significant enough to warrant a label restriction. The standard 1.75 mg as-needed dose applies.

Moderate Renal Impairment (eGFR 30-59 mL/min)

Still no dose adjustment required. AUC increased by approximately 53% in moderate renal impairment. The label permits use at the standard 1.75 mg dose, but your prescriber should counsel you carefully about the side effect profile given the higher drug exposure. Nausea, flushing, and transient blood pressure elevations may be more prominent.

Severe Renal Impairment (eGFR <30 mL/min) and ESRD

Use is not recommended. In women with severe renal impairment, bremelanotide AUC rose by approximately 77% relative to those with normal kidney function. That degree of accumulation raises meaningful concern about amplified cardiovascular and gastrointestinal side effects, and no adequate safety data exist to characterize the risk precisely. Women on dialysis were not studied, so the label cannot provide data-supported guidance for that group.

What "Not Recommended" Means in Practice

"Not recommended" is a softer restriction than "contraindicated." It signals that the FDA did not see sufficient safety data to prohibit use outright, but does not have confidence that the risk-benefit balance is favorable at any tested dose. A lower dose has not been tested in this population, so there is no validated alternative starting point. Your prescriber cannot simply halve the dose and consider the problem solved. The 1.75 mg auto-injector is the only commercially available form.

A practical clinical decision framework for women with CKD considering bremelanotide:

| CKD Stage | eGFR (mL/min) | Label Guidance | Clinical Approach | |---|---|---|---| | G1 (normal) | ≥90 | Standard dose | 1.75 mg as needed | | G2 (mild) | 60-89 | No adjustment | 1.75 mg; routine monitoring | | G3a/G3b (moderate) | 30-59 | No adjustment | 1.75 mg; heightened nausea/BP counseling | | G4 (severe) | 15-29 | Not recommended | Discuss benefit-risk; consider alternatives | | G5/ESRD | <15 or dialysis | Not recommended | Avoid; no data |

Side Effects That Matter More When Your Kidneys Are Impaired

Bremelanotide has a manageable but real side effect burden even in women with normal renal function. With reduced clearance, several effects deserve closer attention.

Nausea

Nausea is the most common adverse event, reported by 40% of women in the Phase 3 RECONNECT trials compared with 1% on placebo. It typically peaks around 1 hour post-injection and resolves within 2 hours. In the RECONNECT program, 12.5% of women in the bremelanotide arm used an antiemetic compared with 1% on placebo. Prescribing an antiemetic (ondansetron 4 mg orally 30 minutes before injection is one common approach, though off-label for this indication) is reasonable for women with moderate CKD given the higher drug exposure and therefore potentially more pronounced nausea.

Transient Blood Pressure Elevation

Bremelanotide produces a mean maximum decrease in blood pressure of approximately 6 mmHg systolic, occurring paradoxically after an initial transient increase. The label states that transient increases in blood pressure of about 2 mmHg mean systolic have been observed, with the largest individual increases seen during the first hour. Women with CKD often have comorbid hypertension. If your blood pressure is not well-controlled, Vyleesi should not be started until it is. The label specifically states the drug should not be used in women with cardiovascular disease or uncontrolled hypertension.

Hyperpigmentation

Focal hyperpigmentation of the face, gums, or breasts occurs in about 1% of women with repeated use. This is a melanocortin-mediated effect. It may not fully reverse after discontinuation. Women with renal impairment using the drug more chronically, even infrequently, should monitor for this.

Flushing

Flushing or hot flush was reported in approximately 20% of RECONNECT trial participants. In perimenopausal women or women on treatment for vasomotor symptoms, distinguishing a bremelanotide-induced flush from a hot flash is clinically relevant.

Life-Stage Considerations

Premenopausal Women (the Approved Population)

Both Phase 3 RECONNECT trials (RECONNECT-1 and RECONNECT-2) enrolled only premenopausal women with generalized acquired HSDD. Across the two trials, women receiving bremelanotide showed a statistically significant increase in satisfying sexual events and a reduction in distress related to low desire compared with placebo. The label approval and the renal PK data therefore apply most directly to you if you are premenopausal with CKD stages G1 through G3b.

Perimenopause

HSDD is especially common during perimenopause. Falling estrogen reduces genital blood flow and central dopaminergic tone, compounding the desire deficit that bremelanotide is meant to address. Bremelanotide is not approved for perimenopausal or postmenopausal women, and women in the menopausal transition were excluded from the RECONNECT trials. If you are perimenopausal with CKD and HSDD, your prescriber may consider addressing hormonal drivers first, since estrogen therapy or testosterone (off-label in the US for women) may improve desire with less kidney-clearance risk.

Postmenopause

No efficacy or safety data from randomized controlled trials exist for postmenopausal women. Use in this group is off-label. Postmenopausal women also have modestly lower eGFR on average than premenopausal women of any given age, making the renal impairment guidance even more likely to apply. This is an area where the evidence gap is genuine and should be named honestly: the combination of postmenopausal status and CKD has not been studied.

PCOS

Women with PCOS are disproportionately affected by metabolic syndrome and early CKD, partly due to insulin resistance and hypertension. HSDD is also reported at higher rates in women with PCOS. A 2023 review in the Journal of Clinical Endocrinology found that women with PCOS had a significantly higher prevalence of sexual dysfunction compared with controls. If you have PCOS with CKD G3 or beyond and are seeking HSDD treatment, the renal impairment table above applies directly to your situation.

Pregnancy, Lactation, and Contraception

Bremelanotide must not be used during pregnancy. This is a hard stop, not a soft caution.

Pregnancy Category and Animal Data

The FDA label classifies bremelanotide as having animal reproductive toxicity data that raise concern. In animal studies, bremelanotide caused fetal malformations, including incomplete ossification and reduced fetal weight, at doses producing exposures lower than those in humans at the 1.75 mg clinical dose. No adequate and well-controlled human pregnancy studies exist, because the drug was not tested in pregnant women.

Because of these animal findings and the lack of human safety data, the label states clearly: avoid use during pregnancy. If you become pregnant while using Vyleesi, stop the drug immediately and contact your provider.

Contraception Requirement

Women of reproductive potential should use effective contraception while using bremelanotide. The label also notes that bremelanotide may reduce the systemic exposure of oral hormonal contraceptives taken within 1 hour of injection, because it slows gastric emptying. The practical instruction is to take your oral contraceptive pill at least 1 hour before or at least 1 hour after bremelanotide injection to avoid this interaction. Women using non-oral contraception (IUD, implant, injectable, patch, ring) do not have this timing concern.

Lactation

No human data exist on whether bremelanotide is present in breast milk, what its effects on a breastfed infant might be, or what effects it has on milk production. The label recommends that women not breastfeed during use of bremelanotide. If you are postpartum, this is a firm contraindication to use while nursing. Postpartum HSDD is common and underrecognized, but bremelanotide is not the answer while breastfeeding.

Trying to Conceive

If you are currently trying to conceive, Vyleesi should be stopped before you begin actively attempting pregnancy. Given its mechanism and the animal reproductive data, it is not a drug to continue while in an active conception cycle.

Who This Is Right For and Who Should Avoid It

This section sorts by life stage and kidney function together, which is the combination most likely to matter to you.

Appropriate Candidates

• Premenopausal women with generalized acquired HSDD, not attributable solely to relationship, psychiatric, or medical causes
• eGFR ≥60 mL/min (G1 or G2 CKD): standard use applies with routine monitoring
• eGFR 30-59 mL/min (G3 CKD): appropriate if blood pressure is controlled, no cardiovascular disease, and patient is counseled about heightened nausea risk
• Not pregnant, not breastfeeding, using reliable contraception

Use With Caution

• eGFR 30-59 mL/min with comorbid hypertension requiring medication: monitor blood pressure response to first dose, ideally in a setting where it can be checked
• Women in late perimenopause with CKD G3: off-label, no trial data; discuss with your gynecologist whether hormonal therapies should be tried first
• Women taking oral contraceptives: time the OCP dose correctly relative to Vyleesi injection

Avoid

• eGFR <30 mL/min (G4 CKD) or ESRD/dialysis
• Uncontrolled hypertension or known cardiovascular disease
• Pregnancy or active conception attempt
• Breastfeeding
• Postmenopausal women: off-label with no safety data in this group with CKD

Monitoring Recommendations for Women With CKD Using Vyleesi

Your prescriber should establish a baseline before starting bremelanotide and revisit it at each refill or check-in.

Baseline Assessment

• Current eGFR (within the past 3-6 months, or sooner if rapidly progressive kidney disease)
• Blood pressure, ideally on two separate occasions
• A clear HSDD diagnosis using a validated tool such as the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), which was used as an endpoint in the RECONNECT trials
• Medication reconciliation, specifically for drugs affecting blood pressure and oral contraceptives

First-Use Monitoring

For women with G3 CKD in particular, considering self-monitoring of blood pressure at 30, 60, and 90 minutes after the first injection is sensible. The transient BP fluctuation is greatest with the first dose.

Ongoing

• Reassess eGFR annually or per your nephrologist's schedule; if eGFR declines below 30, the prescriber should stop the drug
• Skin examination for hyperpigmentation at each visit if using repeatedly over months
• Reassess HSDD response using the same validated scale at 8 weeks; the RECONNECT trials showed that women who responded did so by week 4-8, so prolonged use without benefit is not warranted

The Evidence Gap: What We Do Not Know

Women with CKD and HSDD represent a group the original clinical development program did not study in depth. The renal impairment data come from a pharmacokinetic sub-study, not from a randomized controlled trial of efficacy or safety in women with CKD and HSDD. That distinction matters. We know bremelanotide accumulates more in the renal-impaired body. We do not have trial data confirming the same efficacy-to-risk ratio holds in that group as it does in women with normal kidneys.

Postmenopausal women were excluded from both RECONNECT key trials, which means the intersection of postmenopausal status, CKD, and HSDD treatment with bremelanotide is essentially unstudied. This is an honest limitation that your prescriber should acknowledge, not paper over.

Women have historically been underrepresented in pharmacokinetic sub-studies, particularly those conducted alongside early-phase trials. The fact that the bremelanotide renal PK study did include women is a strength. Still, sample sizes in dedicated renal impairment PK studies are typically small, often 6-12 subjects per group, and the confidence intervals around the AUC increase percentages reported in the label are wide enough that individual variability could be meaningfully larger than the point estimates suggest.

Alternatives for Women With Severe Renal Impairment and HSDD

If your eGFR places you in the "not recommended" category for bremelanotide, HSDD still deserves treatment. Options that do not depend on renal clearance to the same extent include:

Flibanserin (Addyi): Also FDA-approved for HSDD in premenopausal women. Flibanserin is metabolized primarily by CYP3A4 and excreted mainly in urine as metabolites. Severe hepatic impairment contraindicates use, but no renal dose adjustment is specified in the label. For women with CKD who cannot use bremelanotide, flibanserin may be discussable with your prescriber, though the hepatic and CNS side effect profile (sedation, hypotension, syncope, especially with alcohol) creates its own set of considerations.

Off-label testosterone: A 2019 global consensus statement in the Journal of Clinical Endocrinology and Metabolism supports transdermal testosterone for postmenopausal HSDD. Testosterone is not cleared primarily by the kidneys, making it potentially more suitable for women with CKD, though no formal renal impairment dosing studies exist for female sexual function specifically.

Psychosexual therapy and couples-based interventions: The ACOG Committee Opinion on female sexual dysfunction recognizes that psychological and relational factors often intertwine with biological ones in HSDD. For women in whom pharmacotherapy carries meaningful risk, a course of sex-positive therapy with a certified sex therapist is a first-line option with no renal risk.

The decision between these paths depends on your eGFR, your comorbidities, your hormonal status, and how much distress the desire deficit is causing you. That calculation belongs in a conversation with a prescriber who knows your full medical picture.